PharmaVOICE - 
February 2017
Purchase Issue

In Every Issue
Letter from the Editor
Creating an experience What do customers want? This is a [...]
By

Taren Grom, Editor

Upfront
Trends in Biopharma Innovation Over the last 20 years, a [...]
By

PharmaVOICE Staff

Innovator’s Corner
Gene Therapy for Better Sight Kathy High, M.D., President and [...]
By

Kathy High, M.D., President and Chief Scientific Officer at Spark Therapeutics

HealthTech
Google Trains AI to Spot Diabetic Retinopathy Trendwatch: From eye [...]
By

PharmaVOICE Staff

Last Word
A Code of Ethics Mike Rea, CEO of IDEA Pharma, [...]
By

Mike Rea, CEO, IDEA Pharma

On The Cover

C-Suite Outlook: Leading Through Extraordinary Change
Sustaining Value According to Deloitte, life-sciences companies are evolving their business models from product development through manufacturing and distribution, to move “beyond the pill”  and to engage more fully with providers and patients throughout the product lifecycle and “transform what is possible.” Recent figures indicate these efforts may be starting to pay off. The current [...]
By

PharmaVOICE Staff

Features

The Creative Process
As challenging as creating a great piece of marketing is, over the years some pharma brands have still managed to nail it. According to a 2016 AdWeek CMO report, there are several examples of award-winning, but most importantly, memorable campaigns over the years that have successfully boosted brand recognition and as a result increased product [...]
By

Robin Robinson

The Next Generation of Cancer Immunotherapy
Researchers and drug developers are gaining a better understanding of the immune system and how to better target cancer; as a result, immuno-oncology continues to be a key area of anticancer drug development. Researchers over the last few years have found that the immune system has the capability to detect and destroy abnormal cells, but [...]
By

Denise Myshko

Update on Zika Research
First identified in Uganda in 1947, the Zika virus over the past two years has rapidly spread through Asia, the South Pacific, Hawaii, South America, Central America, and the Caribbean. In 2016, active local mosquito-borne transmission began to occur in North America, specifically in Florida and Texas. According to the World Health Organization (WHO), as [...]
By

Denise Myshko

Rare Disease Day Turns Spotlight on Research
On the last day in February, hundreds of patients’ groups from around the world will hold a host of activities to raise awareness about rare diseases. The international 10th annual Rare Disease Day, which is coordinated by the European Organization for Rare Diseases (EURORDIS), seeks to help the public understand how rare diseases impact people’s [...]
By

Kim Ribbink

SHOWCASE FEATURE: Outsourcing: The Outsourcing Big Picture
Outsourcing is now firmly entrenched in the pharma industry. While pharmaceutical companies have been outsourcing back-office activities for many years now, they are increasingly turning to external partners for research and development activities that traditionally were retained in-house. Today, the pharmaceutical and biotech industry has the highest level of R&D outsourcing across all high-technology industries, [...]
By

PharmaVOICE Staff

Partnering for More Impactful Patient Recruitment Services
Sponsors of global clinical trials increasingly need a strategic partner for their patient enrollment challenges, as opposed to enlisting an array of outsourced tactical vendors through a standard RFP process. Why have such partnerships become critical for on-time trial completion? There are a number of reasons. In general, the industry’s standard approach to recruitment is [...]
By

Elaina N. Haeuber, Executive Director of Strategic Operations, Acurian

Smart Will Win!
The more this industry changes, the more it stays the same. The companies that apply their intelligence to winning the transactional nature of our business will ultimately succeed. Whether you study the pharmaceutical and biotech industry from the top down or the bottom up, you will find that applying the good business principles that have [...]
By

Peter Marchesini, Chief Operating Officer, Alamo Pharma Services

An Outsourcing Evolution: Why Improving Yesterday’s Model Addresses Tomorrow’s Needs
Under the traditional model for drug delivery and commercialization, there are many opportunities for patients to slip through the cracks. In the rare disease sector specifically, therapies typically flow through a half-dozen disjointed, uncoordinated middlemen, including wholesalers, distributors, hubs, specialty pharmacies, and healthcare providers before they get to a patient. It’s no wonder then that [...]
By

Danny Williams, Chief Sales & Marketing Officer and Penny Demus, Senior VP, Business Development, Dohmen Life Science Services

3-D Outsourcing: The Key to Improved Product Launches
Put yourself in this situation: You are the director of operations at a growing biotech company. It is either your first product launch or your previous product launches have been slow, inefficient and costly. It is up to you to improve commercialization by streamlining processes and using limited resources more effectively. You have three options: [...]
By

Steve Devrieze, VP, Emerging Biopharma and Technologies for Integrated Engagement Services North America, and Paul Harney, VP, Business Development for Integrated Engagement Services North America, QuintilesIMS

Speak Out
Maximizing Patient Recruitment in Rare Disease Research Creating a pharmaceutical develop- ment program for the treatment of a rare disease is challenging. From re-cruiting and retaining patients and investi- gators, through to regulatory uncertainties and limited understanding of the natural history of the proposed indication due to few observational trials studying disease progression, there are [...]
By

Jeffrey Zucker, Vice President, Feasibility and Recruitment Optimization, and Barbara Zupancic, Director, Global Patient Recruitment and Retention, Worldwide Clinical Trials

FEEDBACK